Bet on Earnings, No...
Health Care: Drugs
Osiris Therapeutics Inc. (OSIR: NASDAQ)
$10.65 0.37 | 3.60%
06/18/13 - 04:00 PM ET
245.99K / 102.90K
Vol / Avg. Vol:10.27 / 10.28
Open / Prev. Close:10.13 - 10.89
Today's Range:6.55 - 14.46
52 Wk Range:14.48%
Performance YTD:TheStreet Rating:
Portfolios with OSIR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- User2012
- ContributorStocks Rising On Unusual Vo...
- UserPharma
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Moving Hig...
- UserE*Trade
- Contributor200 day moving average stocks
Latest OSIR Headlines from TheStreet
- Osiris Therapeutics Inc. Stock Upgraded (OSIR) 03.28.13 | 05:03 am
- 4 Stocks Spiking on Unusual Volume 03.11.13 | 02:03 pm
- Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta 03.08.13 | 06:03 am
- Osiris Therapeutics Inc. Stock Downgraded (OSIR) 03.08.13 | 04:03 am
- 10 Biotech Stocks With A History Of Beating Earning Expectations 01.10.13 | 07:01 pm
- 5 Under-$10 Stocks Due to Surge 12.27.12 | 01:12 pm
- The Next Big Thing In Biotech: Worst CEO Candidates
11.23.12 | 05:11 am - Biotech Stock Mailbag: More Amarin, MannKind, Orexigen 11.02.12 | 07:11 am
- Biotech Stock Mailbag: Sarepta Bear Story, Vertex, Osiris 10.05.12 | 06:10 am
- Biotech Stock Mailbag: Mela, Osiris, Talon 08.03.12 | 06:08 am
Press Releases for OSIR
- Osiris Therapeutics To Present At The Canaccord Genuity Musculoskeletal Conference - Business Wire 03.14.13 | 07:03 am
- Osiris Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.06.13 | 08:03 am
- Osiris Therapeutics Establishes Direct Sales Force For Grafix® - Business Wire 03.01.13 | 07:03 am
- Osiris Therapeutics Announces Fourth Quarter And Full Year 2012 Financial Results Conference Call - Business Wire 02.22.13 | 05:02 pm
- Osiris Therapeutics Receives Title Of European Orphan Drug Designation For Prochymal® - Business Wire 02.19.13 | 07:02 am
- Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge - Business Wire 02.18.13 | 07:02 pm
- Osiris Therapeutics To Present At The 24th Annual Piper Jaffray Healthcare Conference - Business Wire 11.20.12 | 04:11 pm
- Osiris Therapeutics Reports Third Quarter 2012 Financial Results - Business Wire 11.05.12 | 08:11 am
- Osiris Therapeutics Announces Third Quarter 2012 Financial Results Conference Call - Business Wire 10.29.12 | 04:10 pm
- Osiris Therapeutics Names Lode Debrabandere Chief Operating Officer - Business Wire 10.22.12 | 04:10 pm
Partner Headlines for OSIR
- Cell Therapy Leader Stephen Potter Talks Osiris, NeoStem And The Industry Itself - Seeking Alpha 03.19.13 | 09:03 am
- Acute Radiation Syndrome, Are We Prepared And Who Is Best Preparing Us? - Seeking Alpha 02.27.13 | 09:02 am
- Mid-Week Biopharma Catalyst Trades To Consider - Seeking Alpha 12.13.12 | 09:12 am
- Orphan Status Update from Pluristem - Analyst Blog - Zacks 11.27.12 | 07:11 pm
- Neutral on Osiris - Analyst Blog - NASDAQ 09.10.12 | 09:09 pm
- Cell Therapy Outlook Starting To Match Clinical Results - Seeking Alpha 08.21.12 | 09:08 am
- These Are Four of the Hottest Biotechs in the Market Right Now - Benzinga 07.05.12 | 01:07 pm
- Healthcare Biz Review: Osiris ACCUSED, Chelsea's BAD NEWS - Wall St. Cheat Sheet 07.04.12 | 08:07 am
- Osiris' Prochymal Encourages - Analyst Blog - Zacks 07.03.12 | 05:07 pm
- 6 Profitable Small Cap Healthcare Stocks Holding Large Cash Reserves - Seeking Alpha 06.22.12 | 07:06 pm
